Selma Bouden, Lilia Laadhar, Jihene Soua, Meriam Ben Messaoud, Leila Rouached, Imene Ayadi, Olfa Saidane, Aicha Ben Tekaya, Ines Mahmoud, Sonia Rekik, Héla Sahli Srairi, Rawdha Tekaya, Syrine Bellakhal, Monia Fekih, Leila Abdelmoula, Maryem Kallel
INTRODUCTION: Tumor necrosis factor alpha (TNF alpha) blockers such as infliximab (IFX) and adalimumab (ADA) had significantly changed the course of inflammatory diseases such as rheumatoid arthritis (RA), spondyloarthritis (SpA) and Crohn's disease (CD). However, about 30% of patients do not respond to these treatments. This lack of response may be due to the formation of antibodies against these drugs (anti-drug antibodies: ADAbs). The aim of this study was to determine the prevalence of ADAbs against IFX and ADA, and the trough serum concentration of IFX and ADA in RA, SpA or CD patients and to assess their impact on the therapeutic response...
January 2, 2024: Current Rheumatology Reviews